Author

Kimberly J. Briggs

Tango Therapeutics (United States)ORCID 0009-0007-4564-6576Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

Alan HuangiD· 1 shared Jannik N. AnderseniD· 1 shared John P. MaxwelliD· 1 shared Kevin M. CottrelliD· 1 shared Luisa CimminoiD· 1 shared Matthew R. ToniniiD· 1 shared Samuel R. MeieriD· 1 shared Shangtao LiuiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

8 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alan HuangORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintMar 30, 2026

Identification of a lineage-agnostic splicing signature caused by PRMT5 inhibition

Matthew R. Tonini, Samuel R. Meier, Shangtao Liu…·Kimberly J. Briggs

This paper identifies a splicing signature caused by PRMT5 inhibition in MTAP-deleted cancers, showing histology-agnostic splicing changes and potential as a biomarker for PRMT5 inhibitor activity.

DOI 10.64898/2026.03.26.714409

humanbulk RNA-seq

𝕏 PostBluesky